Search AMGN
AMGEN INC
Nasdaq · CIK 318154
Last close403.04
Daily change-4.23 (-1.04%)
10 Years gain+184.16%
Dividends TTM9.94 (+5.86%)
Dividend yield2.44%
Fundamental Analysis
AMGN · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
45.8Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue19
Quarterly Revenue75
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth16.0 / 25
Quality6.4 / 25
Capital Efficiency7.8 / 20
Balance Sheet5.2 / 15
Shareholder Economics8.1 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 7.9979 percentage points.
Operating leverageOperating margin improved by 11.5195 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM15.15%OK
Revenue CAGR 3Y11.77%OK
Gross Margin68.86%OK
Operating Margin30.37%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC16.35%OK
Incremental Operating Margin 3Y14.69%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.55%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $36.75B | $24.71B | $9.08B | $9.96B | $8.10B | 67.25% | 24.71% | 22.04% | 14.43% | 542M |
| 2025 FY Dec 31, 2024 | $33.42B | $20.57B | $7.26B | $11.49B | $10.39B | 61.53% | 21.71% | 31.1% | 11.31% | 541M |
| 2025 FY Dec 31, 2023 | $28.19B | $19.74B | $7.90B | $8.47B | $7.36B | 70.02% | 28.01% | 26.11% | 14.49% | 538M |
| 2024 FY Dec 31, 2022 | $26.32B | $19.92B | $9.57B | $9.72B | $8.79B | 75.66% | 36.34% | 33.37% | 26.14% | 541M |
| 2023 FY Dec 31, 2021 | $25.98B | $19.53B | $7.64B | $9.26B | $8.38B | 75.16% | 29.4% | 32.26% | 21.09% | 573M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $37.41B | sum latest 4 fiscal quarters Revenue | OK | 0000318154-26-000126, 0000318154-25-000072 |
| Revenue Growth TTM | 15.15% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000318154-26-000126, 0000318154-25-000072 |
| Revenue CAGR 3Y | 11.77% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000318154-26-000010 |
| Revenue CAGR 5Y | 7.65% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000318154-26-000010 |
| Gross Profit CAGR 3Y | 7.46% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000318154-26-000010 |
| Operating Income Growth | 85.5% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000318154-26-000126, 0000318154-25-000072 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 68.86% | Gross Profit / Revenue | OK | 0000318154-26-000126, 0000318154-25-000072 |
| Operating Margin | 30.37% | Operating Income / Revenue | OK | 0000318154-26-000126, 0000318154-25-000072 |
| ROIC | 16.35% | NOPAT / Average Invested Capital | OK | 0000318154-26-000126, 0000318154-25-000072 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000318154-26-000126 |
| Current Ratio | 1.37x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.24x | (Cash + Short-term Investments) / Total Debt | OK | 0000318154-26-000126 |
| Revenue per Diluted Share | $68.76 | Revenue / Diluted Shares | OK | 0000318154-26-000126, 0000318154-25-000072 |